Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Corti

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Targeted Oncology|August 4, 2018
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy ApproachesDaniela Femia, Natalie Prinzi, Andrea Anichini, et al.
Therapeutic Advances in Medical Oncology|December 18, 2020
Antitumor activity and efficacy of shorter <i>versus</i> longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysisRiccardo Lobefaro, Emma Zattarin, Federico Nichetti, et al.
Journal of Clinical Medicine|August 6, 2020
Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine TumorsSara Pusceddu, Roberta Elisa Rossi, Martina Torchio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Clinical Lung Cancer|February 23, 2021
Recent Advances in the Management of Typical and Atypical Lung CarcinoidsNatalie Prinzi, Roberta Elisa Rossi, Claudia Proto, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Frontiers in Oncology|February 21, 2022
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future PerspectiveMichele Prisciandaro, Maria Antista, Alessandra Raimondi, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Targeted Oncology|August 4, 2018
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy ApproachesDaniela Femia, Natalie Prinzi, Andrea Anichini, et al.
Therapeutic Advances in Medical Oncology|December 18, 2020
Antitumor activity and efficacy of shorter <i>versus</i> longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysisRiccardo Lobefaro, Emma Zattarin, Federico Nichetti, et al.
Journal of Clinical Medicine|August 6, 2020
Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine TumorsSara Pusceddu, Roberta Elisa Rossi, Martina Torchio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
Clinical Lung Cancer|February 23, 2021
Recent Advances in the Management of Typical and Atypical Lung CarcinoidsNatalie Prinzi, Roberta Elisa Rossi, Claudia Proto, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Frontiers in Oncology|February 21, 2022
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future PerspectiveMichele Prisciandaro, Maria Antista, Alessandra Raimondi, et al.
Pageof 7